Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?

We report here a 44-year-old Moroccan man with resectable gastric adenocarcinoma with overexpression of human epidermal growth factor receptor 2 (HER2) by immunohistochemistry who was treated with trastuzumab in combination with chemotherapy in perioperative setting. He received 3 cycles of neoadjuv...

Full description

Bibliographic Details
Main Authors: Sbitti, Yassir, Essaidi l, Ismail, Debbagh, Adil, Kadiri, Habiba, Oukabli, Mohamed, Moussaid, Yassine, Slimani, Khaoula, Fetohi, Mohamed, Elkaoui, Hakim, Albouzidi, Abderrahmane, Mahi, Mohamed, Ali, Abdelmounaim Ait, Ichou, Mohamed, Errihani, Hassan
Format: Online
Language:English
Published: BioMed Central 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204255/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204255/

Similar Items